

FOR IMMEDIATE RELEASE

Vystar Corporation
Betty Orsey
(678) 427-1766
borsey@pointagency.com

Vystar Corporation
Colleen Golden
(404) 888-1700 x111
cgolden@pointagency.com

VYTEX™ NATURAL RUBBER LATEX MANUFACTURING TEST RESULTS GET INTERNATIONAL LATEX CONFERENCE BUZZING

Cleveland, Ohio, July 24, 2008 — Immunochemist Mark C. Swanson got leading scientists and researchers at the International Latex Conference 2008 excited about a bright future for natural rubber latex (NRL) yesterday with insights into the development and practical applications of Vytex™ NRL from Vystar Corporation. This commercially available NRL source material has ultra low antigenic protein levels as raw material while preserving desirable NRL properties in finished products.

Vystar Chief Executive Officer William Doyle said, “We are very fortunate to have a scientist of Mark’s stature engaged in evaluating and testing Vytex NRL. Mark is a highly-regarded researcher in latex protein interaction who is frequently called upon by employers and agencies to evaluate workplace bioaerosols and their remedies.”

Presenting to the conference, Swanson called Vytex NRL a standardized source material for the production of natural rubber products using NRL that is modified to significantly reduce its antigenic protein content. He pointed out that this innovative product, currently being produced under a toll manufacturing agreement with Revertex Malaysia, can be used in a wide array of medical and non-medical applications.

Vytex NRL is produced at the latex processor level and can be easily integrated into current manufacturing environments without additional capital equipment investment. The multi-patented modification process that leads to Vytex NRL also has the potential to allow manufacturers to lower manufacturing costs with reductions in process time, energy, water and material handling consumption.

Altogether, more than 500 medical and non-medical products made with Vytex NRL have been independently tested using accredited ASTM protein test methodologies. Among the products produced and tested are surgical gloves, condoms, foam (as used in mattresses and pillows), adhesives, tubing, probe covers and breather bags. Swanson reported that test results show that in addition to significantly reduced antigenic protein levels; products made with Vytex NRL demonstrate improved physical properties important to end-product quality such as tensile strength and resistance to aging when compared to non-Vytex NRL.

The full text of the technical paper Swanson delivered, *Vytex™ Natural Rubber Latex*:



An Innovative Source Material for Natural Rubber Products, is now available online at www.vytex.com. Swanson and Doyle co-authored the paper along with Industry Consultant Russell Culp and Vystar Vice President, Technical Services, Matthew Clark.

Vystar Corp. is the exclusive creator of the innovative technology to produce Vytex Natural Rubber Latex™ (NRL). While latex allergy is most common in the healthcare industry because of workers prolonged and/or repeated contact with latex, it is estimated that as many as 17 percent of healthcare workers and three percent of the general population could have an allergic reaction to the protein in natural rubber latex. However, because of its superior product qualities, like barrier protection, strength and durability, fit and comfort, environmental impact, cost, etc., it is the material of choice for a vast array of everyday products.

About Mark Swanson: Mark C. Swanson is an immunochemist of 30 years working for the Mayo Foundation, Rochester, MN. He holds degrees from St. Cloud State University, in bio-medical science and chemistry. He founded Quan-Tec-Air, Inc. in 1985. The company is dedicated to the quantification of asthmagenic bio-aerosols using specialized sampling, filtration and immunoassay techniques. The combination of air sampling expertise and de novo immunoassay design and implementation makes him a unique and valuable resource for immuno-aero-biological health hazard assessment.

About Vystar Corporation: Vystar Corporation, incorporated in 2003, is a privately funded corporation located in the Atlanta area. It is included in the portfolio of Universal Capital Management, Inc. (OTC BB:UCMT.OB), a business development company that provides management and strategic growth resources to emerging growth companies. The company's operations have been focused substantially on early-stage research, development, testing and commercialization of the Vytex NRL process. Vystar, named a 2007 Top 10 Innovative Technology Company in Georgia by the Technology Association of Georgia (TAG), holds two U.S. patents for the Vytex™ NRL technology, with two additional filings pending. For more information, please visit www.vytex.com.

Forward-looking Statements: Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as Vystar Corporation "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe Vystar's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Vystar as appropriate, which could cause actual results to differ materially from those currently anticipated. Although Vystar believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and Vystar does not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

